Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.
Publication/Presentation Date
11-11-2024
Abstract
Intratumoral TLR9 agonists and anti-PD-1 produce clinical responses and broad immune activation. We conducted a single-arm study of neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab in high-risk resectable melanoma. In 31 evaluable patients, 55% major pathologic response (MPR) was observed, meeting primary endpoint. MPR was associated with necrosis, and melanophagocytosis with increased CD8
Volume
42
Issue
11
First Page
1898
Last Page
1918
ISSN
1878-3686
Published In/Presented At
Davar, D., Morrison, R. M., Dzutsev, A. K., Karunamurthy, A., Chauvin, J. M., Amatore, F., Deutsch, J. S., Das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., Wang, H., Hartman, D. J., Badger, J. H., Fernandes, M. R., Bai, Y., Sun, J., Cole, A. M., Aggarwal, P., Fang, J. R., Deitrick, C., … Zarour, H. M. (2024). Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer cell, 42(11), 1898–1918.e12. https://doi.org/10.1016/j.ccell.2024.10.007
Disciplines
Medicine and Health Sciences
PubMedID
39486411
Department(s)
Fellows and Residents
Document Type
Article